Log in with your email address username.


[Comment] Treatment concentration of high-sensitivity C-reactive protein

The landmark CANTOS trial evaluated the use of canakinumab, a monoclonal antibody targeting interleukin 1β, in 10 061 patients with previous myocardial infarction who had high-sensitivity C-reactive protein (hsCRP) concentrations of 2 mg/L or higher.1 Interleukin 1β has multiple potential mechanisms that contribute to the pathogenesis of atherothrombotic cardiovascular disease.2 Induction of interleukin 6 leads to the release of acute phase reactants including hsCRP. Thus, hsCRP serves as a surrogate marker of the overall inflammatory milieu,2 often in situations where patients have multiple co-morbidities,3 with a cumulative dose-response indicating a higher risk.